{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:57:46Z","timestamp":1791316666065,"version":"4.3.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40265-022-01757-5","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T11:03:52Z","timestamp":1663326232000},"page":"1237-1249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?"],"prefix":"10.1007","volume":"82","author":[{"given":"Nguyen Thi Thuy","family":"Ngan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnaby","family":"Flower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7843-6280","authenticated-orcid":false,"given":"Jeremy N.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"issue":"4","key":"1757_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","volume":"23","author":"BJ Park","year":"2009","unstructured":"Park BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS. AIDS. 2009;23(4):525\u201330.","journal-title":"AIDS"},{"issue":"8","key":"1757_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham R, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873\u201381.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1757_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12879-018-3633-4","volume":"19","author":"J Soria","year":"2019","unstructured":"Soria J, et al. Mortality in hospitalized patients with tuberculous meningitis. BMC Infect Dis. 2019;19(1):9.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1757_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10096-014-2238-0","volume":"34","author":"M Bak\u0131r","year":"2015","unstructured":"Bak\u0131r M, et al. Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean-Congo hemorrhagic fever (CCHF). Eur J Clin Microbiol Infect Dis. 2015;34(2):325\u201330.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 5","key":"1757_CR5","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom QT, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016. Neuro Oncol. 2019;21(Suppl 5):v1\u2013100.","journal-title":"Neuro Oncol"},{"issue":"14","key":"1757_CR6","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","volume":"368","author":"JN Day","year":"2013","unstructured":"Day JN, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368(14):1291\u2013302.","journal-title":"N Engl J Med"},{"issue":"11","key":"1757_CR7","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","volume":"378","author":"SF Molloy","year":"2018","unstructured":"Molloy SF, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2018;378(11):1004\u201317.","journal-title":"N Engl J Med"},{"key":"1757_CR8","first-page":"175","volume":"16","author":"O Busse","year":"1894","unstructured":"Busse O. Uber parasitare zelleinschlusse und ihre zuchtung. Zentralbl Bakteriol. 1894;16:175\u201380.","journal-title":"Zentralbl Bakteriol"},{"issue":"7","key":"1757_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019760","volume":"4","author":"KJ Kwon-Chung","year":"2014","unstructured":"Kwon-Chung KJ, et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med. 2014;4(7): a019760.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"1757_CR10","doi-asserted-by":"publisher","first-page":"e357-16","DOI":"10.1128\/mSphere.00357-16","volume":"2","author":"KJ Kwon-Chung","year":"2017","unstructured":"Kwon-Chung KJ, et al. The case for adopting the \u201cspecies complex\u201d nomenclature for the etiologic agents of Cryptococcosis. mSphere. 2017;2(1):e357-16.","journal-title":"mSphere"},{"issue":"1","key":"1757_CR11","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/s41467-019-10092-5","volume":"10","author":"PM Ashton","year":"2019","unstructured":"Ashton PM, et al. Three phylogenetic groups have driven the recent population expansion of Cryptococcus neoformans. Nat Commun. 2019;10(1):2035.","journal-title":"Nat Commun"},{"issue":"1","key":"1757_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055579","volume":"8","author":"T Schoffelen","year":"2013","unstructured":"Schoffelen T, et al. Cryptococcus gattii induces a cytokine pattern that is distinct from other cryptococcal species. PLoS ONE. 2013;8(1): e55579.","journal-title":"PLoS ONE"},{"issue":"9","key":"1757_CR13","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1172\/JCI136221","volume":"130","author":"LA Pirofski","year":"2020","unstructured":"Pirofski LA, Casadevall A. The state of latency in microbial pathogenesis. J Clin Invest. 2020;130(9):4525\u201331.","journal-title":"J Clin Invest"},{"issue":"49","key":"1757_CR14","doi-asserted-by":"publisher","first-page":"17258","DOI":"10.1073\/pnas.0402981101","volume":"101","author":"SE Kidd","year":"2004","unstructured":"Kidd SE, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A. 2004;101(49):17258\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1757_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s11908-011-0181-0","volume":"13","author":"EJ Byrnes","year":"2011","unstructured":"Byrnes EJ, Marr KA. The outbreak of Cryptococcus gattii in Western North America: epidemiology and clinical issues. Curr Infect Dis Rep. 2011;13(3):256\u201361.","journal-title":"Curr Infect Dis Rep."},{"issue":"11","key":"1757_CR16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.tim.2011.07.010","volume":"19","author":"V Chaturvedi","year":"2011","unstructured":"Chaturvedi V, Chaturvedi S. Cryptococcus gattii: a resurgent fungal pathogen. Trends Microbiol. 2011;19(11):564\u201371.","journal-title":"Trends Microbiol"},{"issue":"5","key":"1757_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1086\/322597","volume":"33","author":"PG Pappas","year":"2001","unstructured":"Pappas PG, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33(5):690\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1757_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.idc.2015.10.006","volume":"30","author":"EK Maziarz","year":"2016","unstructured":"Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 2016;30(1):179\u2013206.","journal-title":"Infect Dis Clin North Am"},{"issue":"6","key":"1757_CR19","doi-asserted-by":"publisher","first-page":"e0005628","DOI":"10.1371\/journal.pntd.0005628","volume":"11","author":"JN Day","year":"2017","unstructured":"Day JN, et al. Comparative genomics of Cryptococcus neoformans var. grubii associated with meningitis in HIV infected and uninfected patients in Vietnam. PLoS Negl Trop Dis. 2017;11(6):e0005628.","journal-title":"PLoS Negl Trop Dis."},{"issue":"2","key":"1757_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1128\/JCM.01985-10","volume":"49","author":"JN Day","year":"2011","unstructured":"Day JN, et al. Most cases of cryptococcal meningitis in HIV-uninfected patients in Vietnam are due to a distinct amplified fragment length polymorphism-defined cluster of Cryptococcus neoformans var. grubii VN1. J Clin Microbiol. 2011;49(2):658\u201364.","journal-title":"J Clin Microbiol"},{"key":"1757_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/1471-2334-10-199","volume":"10","author":"TT Chau","year":"2010","unstructured":"Chau TT, et al. A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam\u2014high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect Dis. 2010;10:199.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"1757_CR22","first-page":"5243","volume":"14","author":"CL Yang","year":"2017","unstructured":"Yang CL, Wang J, Zou LL. Innate immune evasion strategies against cryptococcal meningitis caused by Cryptococcus neoformans. Exp Ther Med. 2017;14(6):5243\u201350.","journal-title":"Exp Ther Med"},{"issue":"6","key":"1757_CR23","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.4049\/jimmunol.112.6.2260","volume":"112","author":"RD Diamond","year":"1974","unstructured":"Diamond RD, et al. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol. 1974;112(6):2260\u201370.","journal-title":"J Immunol"},{"issue":"1","key":"1757_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1128\/iai.51.1.218-223.1986","volume":"51","author":"KJ Kwon-Chung","year":"1986","unstructured":"Kwon-Chung KJ, Rhodes JC. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun. 1986;51(1):218\u201323.","journal-title":"Infect Immun"},{"issue":"12","key":"1757_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052895","volume":"7","author":"A Moodley","year":"2012","unstructured":"Moodley A, et al. Early clinical and subclinical visual evoked potential and Humphrey\u2019s visual field defects in cryptococcal meningitis. PLoS ONE. 2012;7(12): e52895.","journal-title":"PLoS ONE"},{"issue":"3","key":"1757_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4103\/0974-777X.161739","volume":"7","author":"A Krishnamoorthy","year":"2015","unstructured":"Krishnamoorthy A, Joel A, Abhilash K. Cryptococcal meningitis with multiple cranial nerves palsies: a review of literature. J Glob Infect Dis. 2015;7(3):123\u20134.","journal-title":"J Glob Infect Dis"},{"issue":"1","key":"1757_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1086\/313603","volume":"30","author":"JR Graybill","year":"2000","unstructured":"Graybill JR, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis: the NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30(1):47\u201354.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1757_CR28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7883\/yoken.JJID.2009.59","volume":"62","author":"PY Liu","year":"2009","unstructured":"Liu PY, Yang Y, Shi ZY. Cryptococcal liver abscess: a case report of successful treatment with amphotericin-B and literature review. Jpn J Infect Dis. 2009;62(1):59\u201360.","journal-title":"Jpn J Infect Dis"},{"issue":"3","key":"1757_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4103\/0970-9371.101175","volume":"29","author":"KJ Philip","year":"2012","unstructured":"Philip KJ, et al. Disseminated cryptococcosis presenting with generalized lymphadenopathy. J Cytol. 2012;29(3):200\u20132.","journal-title":"J Cytol"},{"issue":"5","key":"1757_CR30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0272-6386(88)80057-X","volume":"11","author":"JW Smith","year":"1988","unstructured":"Smith JW, Arnold WC. Cryptococcal peritonitis in patients on peritoneal dialysis. Am J Kidney Dis. 1988;11(5):430\u20133.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1757_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1089\/apc.2008.0108","volume":"23","author":"M Gopal","year":"2009","unstructured":"Gopal M, et al. Cryptococcosis of the upper genital tract. AIDS Patient Care STDS. 2009;23(2):71\u20133.","journal-title":"AIDS Patient Care STDS"},{"issue":"10","key":"1757_CR32","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2169\/internalmedicine.56.7356","volume":"56","author":"M Ito","year":"2017","unstructured":"Ito M, et al. Disseminated Cryptococcosis with adrenal insufficiency and meningitis in an immunocompetent individual. Internal medicine (Tokyo, Japan). 2017;56(10):1259\u201364.","journal-title":"Internal medicine (Tokyo, Japan)"},{"issue":"5","key":"1757_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1258\/ijsa.2009.009132","volume":"23","author":"SM Chai","year":"2012","unstructured":"Chai SM, Teoh SC. Ocular cryptococcosis as a presenting manifestation of cryptococcal meningitis in a patient with HIV. Int J STD AIDS. 2012;23(5):377\u20138.","journal-title":"Int J STD AIDS"},{"issue":"1","key":"1757_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12879-016-2126-6","volume":"17","author":"J Qu","year":"2017","unstructured":"Qu J, et al. Comparison of clinical features and prognostic factors in HIV-negative adults with cryptococcal meningitis and tuberculous meningitis: a retrospective study. BMC Infect Dis. 2017;17(1):51.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1757_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/clinids\/23.2.369","volume":"23","author":"C Darras-Joly","year":"1996","unstructured":"Darras-Joly C, et al. Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus. Clin Infect Dis. 1996;23(2):369\u201376.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1757_CR36","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1590\/S0036-46651997000600003","volume":"39","author":"CR Garlipp","year":"1997","unstructured":"Garlipp CR, Rossi CL, Bottini PV. Cerebrospinal fluid profiles in acquired immunodeficiency syndrome with and without neurocryptococcosis. Rev Inst Med Trop Sao Paulo. 1997;39(6):323\u20135.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"26","key":"1757_CR37","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","volume":"370","author":"DR Boulware","year":"2014","unstructured":"Boulware DR, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"3","key":"1757_CR38","first-page":"16","volume":"45","author":"T Vijayan","year":"2013","unstructured":"Vijayan T, Chiller T, Klausner JD. Sensitivity and specificity of a new cryptococcal antigen lateral flow assay in serum and cerebrospinal fluid. MLO Med Lab Obs. 2013;45(3):16\u201320.","journal-title":"MLO Med Lab Obs"},{"key":"1757_CR39","unstructured":"Guidelines on the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2018. Geneva: World Health Organization."},{"issue":"12","key":"1757_CR40","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1093\/cid\/cix613","volume":"65","author":"T Beyene","year":"2017","unstructured":"Beyene T, et al. Inadequacy of high-dose fluconazole monotherapy among cerebrospinal fluid cryptococcal antigen (CrAg)-positive human immunodeficiency virus-infected persons in an Ethiopian CrAg screening program. Clin Infect Dis. 2017;65(12):2126\u20139.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1757_CR41","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/cid\/cix872","volume":"66","author":"RM Wake","year":"2018","unstructured":"Wake RM, et al. High cryptococcal antigen titers in blood are predictive of subclinical cryptococcal meningitis among human immunodeficiency virus-infected patients. Clin Infect Dis. 2018;66(5):686\u201392.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1757_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/jac\/33.2.203","volume":"33","author":"SH Khoo","year":"1994","unstructured":"Khoo SH, Bond J, Denning DW. Administering amphotericin B\u2014a practical approach. J Antimicrob Chemother. 1994;33(2):203\u201313.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1757_CR43","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/cid\/cit019","volume":"56","author":"GP Bisson","year":"2013","unstructured":"Bisson GP, et al. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis. 2013;56(8):1165\u201373.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1757_CR44","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1086\/652652","volume":"50","author":"AT Makadzange","year":"2010","unstructured":"Makadzange AT, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis. 2010;50(11):1532\u20138.","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"1757_CR45","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1378\/chest.54.Supplement_1.296","volume":"54","author":"JD Dutcher","year":"1968","unstructured":"Dutcher JD. The discovery and development of amphotericin B. Dis Chest. 1968;54(suppl 1):296\u20138.","journal-title":"Dis Chest"},{"issue":"2","key":"1757_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1086\/653606","volume":"51","author":"RJ Hamill","year":"2010","unstructured":"Hamill RJ, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2010;51(2):225\u201332.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1757_CR47","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/clinids\/22.2.315","volume":"22","author":"PK Sharkey","year":"1996","unstructured":"Sharkey PK, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996;22(2):315\u201321.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1757_CR48","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1128\/AAC.47.10.3361-3364.2003","volume":"47","author":"P Schwarz","year":"2003","unstructured":"Schwarz P, et al. In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother. 2003;47(10):3361\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1757_CR49","first-page":"561","volume":"49","author":"MW Pound","year":"2011","unstructured":"Pound MW, et al. Overview of treatment options for invasive fungal infections. Med Mycol. 2011;49(6):561\u201380.","journal-title":"Med Mycol"},{"issue":"12","key":"1757_CR50","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1093\/cid\/ciw151","volume":"62","author":"M Merry","year":"2016","unstructured":"Merry M, Boulware DR. Cryptococcal meningitis treatment strategies affected by the explosive cost of flucytosine in the United States: a cost-effectiveness analysis. Clin Infect Dis. 2016;62(12):1564\u20138.","journal-title":"Clin Infect Dis"},{"key":"1757_CR51","unstructured":"Initiative, C.H.A. HIV market report\u2014the state of HIV treatment, testing, and prevention in low- and middle-income countries. 2020."},{"key":"1757_CR52","doi-asserted-by":"publisher","first-page":"68929","DOI":"10.7554\/eLife.68929","volume":"10","author":"NTT Ngan","year":"2021","unstructured":"Ngan NTT, et al. An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. Elife. 2021;10:68929.","journal-title":"Elife"},{"issue":"12","key":"1757_CR53","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","volume":"386","author":"JN Jarvis","year":"2022","unstructured":"Jarvis JN, et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. N Engl J Med. 2022;386(12):1109\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"1757_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJM199707033370103","volume":"337","author":"CM van der Horst","year":"1997","unstructured":"van der Horst CM, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337(1):15\u201321.","journal-title":"N Engl J Med"},{"issue":"9423","key":"1757_CR55","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","volume":"363","author":"AE Brouwer","year":"2004","unstructured":"Brouwer AE, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363(9423):1764\u20137.","journal-title":"Lancet"},{"issue":"8","key":"1757_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002870","volume":"3","author":"F Dromer","year":"2008","unstructured":"Dromer F, et al. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE. 2008;3(8): e2870.","journal-title":"PLoS ONE"},{"issue":"10","key":"1757_CR57","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1128\/AAC.00933-12","volume":"56","author":"WW Hope","year":"2012","unstructured":"Hope WW, et al. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. Antimicrob Agents Chemother. 2012;56(10):5303\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1757_CR58","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/infdis\/jit164","volume":"208","author":"L O'Connor","year":"2013","unstructured":"O\u2019Connor L, et al. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. J Infect Dis. 2013;208(2):351\u201361.","journal-title":"J Infect Dis"},{"issue":"Pt 11","key":"1757_CR59","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1099\/jmm.0.012401-0","volume":"58","author":"M Ellis","year":"2009","unstructured":"Ellis M, et al. A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever. J Med Microbiol. 2009;58(Pt 11):1474\u201385.","journal-title":"J Med Microbiol"},{"issue":"3","key":"1757_CR60","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/cid\/ciy515","volume":"68","author":"JN Jarvis","year":"2019","unstructured":"Jarvis JN, et al. Short-course high-dose liposomal amphotericin B for human immunodeficiency virus-associated cryptococcal meningitis: a phase 2 randomized controlled trial. Clin Infect Dis. 2019;68(3):393\u2013401.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1757_CR61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/cid\/cir745","volume":"54","author":"A Loyse","year":"2012","unstructured":"Loyse A, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2012;54(1):121\u20138.","journal-title":"Clin Infect Dis"},{"key":"1757_CR62","first-page":"9","volume":"62","author":"KE Stott","year":"2018","unstructured":"Stott KE, et al. Population pharmacokinetics and cerebrospinal fluid penetration of fluconazole in adults with cryptococcal meningitis. Antimicrob Agents Chemother. 2018;62:9.","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"1757_CR63","doi-asserted-by":"publisher","first-page":"e2338","DOI":"10.1093\/cid\/ciaa1544","volume":"73","author":"L O'Connor","year":"2021","unstructured":"O\u2019Connor L, et al. Antifungal susceptibility does not correlate with fungal clearance or survival in AIDS-associated cryptococcal meningitis. Clin Infect Dis. 2021;73(7):e2338\u201341.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"1757_CR64","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/imj.15590","volume":"51","author":"CC Chang","year":"2021","unstructured":"Chang CC, et al. Consensus guidelines for the diagnosis and management of cryptococcosis and rare yeast infections in the haematology\/oncology setting, 2021. Intern Med J. 2021;51(Suppl 7):118\u201342.","journal-title":"Intern Med J"},{"issue":"3","key":"1757_CR65","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/649858","volume":"50","author":"JR Perfect","year":"2010","unstructured":"Perfect JR, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291\u2013322.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1757_CR66","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJMoa1509024","volume":"374","author":"J Beardsley","year":"2016","unstructured":"Beardsley J, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med. 2016;374(6):542\u201354.","journal-title":"N Engl J Med"},{"key":"1757_CR67","unstructured":"clinicaltrials.gov. Three induction treatments on cryptococcal meningitis (TITOC). 2019."},{"issue":"5","key":"1757_CR68","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1590\/S0074-02762012000500003","volume":"107","author":"CR Guerra","year":"2012","unstructured":"Guerra CR, et al. Terbinafine inhibits Cryptococcus neoformans growth and modulates fungal morphology. Mem Inst Oswaldo Cruz. 2012;107(5):582\u201390.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"1757_CR69","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5326\/JAAHA-MS-5813","volume":"48","author":"G Olsen","year":"2012","unstructured":"Olsen G, et al. Use of terbinafine in the treatment protocol of intestinal Cryptococcus neoformans in a dog. J Am Anim Hosp Assoc. 2012;48:216\u201320.","journal-title":"J Am Anim Hosp Assoc"},{"issue":"3","key":"1757_CR70","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/mmy\/myv109","volume":"54","author":"J Trevi\u00f1o-Rangel Rde","year":"2016","unstructured":"Trevi\u00f1o-Rangel Rde J, et al. Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays. Med Mycol. 2016;54(3):280\u20136.","journal-title":"Med Mycol"},{"issue":"7","key":"1757_CR71","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1128\/AAC.00212-12","volume":"56","author":"B Zhai","year":"2012","unstructured":"Zhai B, et al. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother. 2012;56(7):3758\u201366.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1757_CR72","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S1473-3099(16)00074-8","volume":"16","author":"J Rhein","year":"2016","unstructured":"Rhein J, et al. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect Dis. 2016;16(7):809\u201318.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"1757_CR73","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S1473-3099(19)30127-6","volume":"19","author":"J Rhein","year":"2019","unstructured":"Rhein J, et al. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infect Dis. 2019;19(8):843\u201351.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1757_CR74","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s15010-017-1059-3","volume":"46","author":"H Villanueva-Lozano","year":"2018","unstructured":"Villanueva-Lozano H, et al. Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: a single Mexican center experience. Infection. 2018;46(1):25\u201330.","journal-title":"Infection"},{"issue":"6","key":"1757_CR75","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1042\/bst0171038","volume":"17","author":"H Wiseman","year":"1989","unstructured":"Wiseman H, Cannon M, Arnstein HRV. Observation and significance of growth inhibition of Saccharomyces cerevisiae (A224A) by the antioestrogen drug tamoxifen. Biochem Soc Trans. 1989;17(6):1038\u20139.","journal-title":"Biochem Soc Trans."},{"issue":"8","key":"1757_CR76","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1128\/AAC.01564-08","volume":"53","author":"K Dolan","year":"2009","unstructured":"Dolan K, et al. Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrob Agents Chemother. 2009;53(8):3337\u201346.","journal-title":"Antimicrob Agents Chemother."},{"key":"1757_CR77","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/msb.2011.31","volume":"7","author":"M Spitzer","year":"2011","unstructured":"Spitzer M, et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol. 2011;7:499.","journal-title":"Mol Syst Biol"},{"issue":"9","key":"1757_CR78","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/myc.12955","volume":"62","author":"TP Hai","year":"2019","unstructured":"Hai TP, et al. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans. Mycoses. 2019;62(9):818\u201325.","journal-title":"Mycoses"},{"issue":"1","key":"1757_CR79","doi-asserted-by":"publisher","first-page":"e00765-13","DOI":"10.1128\/mBio.00765-13","volume":"5","author":"A Butts","year":"2014","unstructured":"Butts A, et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. MBio. 2014;5(1):e00765-13.","journal-title":"MBio"},{"issue":"8","key":"1757_CR80","doi-asserted-by":"publisher","first-page":"00312-18","DOI":"10.1128\/AAC.00312-18","volume":"62","author":"CC Spadari","year":"2018","unstructured":"Spadari CC, et al. Miltefosine has a postantifungal effect and induces apoptosis in cryptococcus yeasts. Antimicrob Agents Chemother. 2018;62(8):00312\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"1757_CR81","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1128\/AAC.50.2.414-421.2006","volume":"50","author":"F Widmer","year":"2006","unstructured":"Widmer F, et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother. 2006;50(2):414\u201321.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1757_CR82","doi-asserted-by":"publisher","first-page":"1921-19","DOI":"10.1128\/AAC.01921-19","volume":"64","author":"SA Rossi","year":"2020","unstructured":"Rossi SA, et al. Identification of off-patent drugs that show synergism with amphotericin B or that present antifungal action against Cryptococcus neoformans and Candida spp. Antimicrob Agents Chemother. 2020;64(4):1921\u201319.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1757_CR83","doi-asserted-by":"publisher","first-page":"1909-17","DOI":"10.1128\/AAC.01909-17","volume":"62","author":"GL Nixon","year":"2018","unstructured":"Nixon GL, et al. Repurposing and reformulation of the antiparasitic agent flubendazole for treatment of cryptococcal meningoencephalitis, a neglected fungal disease. Antimicrob Agents Chemother. 2018;62(4):1909\u201317.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1757_CR84","doi-asserted-by":"publisher","first-page":"2372-18","DOI":"10.1128\/AAC.02372-18","volume":"63","author":"M Zhao","year":"2019","unstructured":"Zhao M, et al. APX001 pharmacokinetic\/pharmacodynamic target determination against Aspergillus fumigatus in an in vivo model of invasive pulmonary Aspergillosis. Antimicrob Agents Chemother. 2019;63(4):2372\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1757_CR85","doi-asserted-by":"publisher","first-page":"e00523","DOI":"10.1128\/AAC.00523-18","volume":"62","author":"KJ Shaw","year":"2018","unstructured":"Shaw KJ, et al. In vitro and in vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against Cryptococcus. Antimicrob Agents Chemother. 2018;62(8):e00523-e618.","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"1757_CR86","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","volume":"81","author":"M Hoenigl","year":"2021","unstructured":"Hoenigl M, et al. The antifungal pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. 2021;81(15):1703\u201329.","journal-title":"Drugs"},{"issue":"8","key":"1757_CR87","doi-asserted-by":"publisher","first-page":"52318","DOI":"10.1128\/AAC.00523-18","volume":"62","author":"KJ Shaw","year":"2018","unstructured":"Shaw KJ, et al. In vitro and in vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against Cryptococcus. Antimicrob Agents Chemother. 2018;62(8):52318.","journal-title":"Antimicrob Agents Chemother"},{"key":"1757_CR88","unstructured":"clinicaltrials.gov. Safety, pharmacokinetics, bioavailability, food effect, drug\u2013drug interaction study of APX001 administered orally. 2016. Amplyx Pharmaceuticals."},{"issue":"2","key":"1757_CR89","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1099\/mic.0.000222","volume":"162","author":"RA Cordeiro","year":"2016","unstructured":"Cordeiro RA, et al. Inhibition of heat-shock protein 90 enhances the susceptibility to antifungals and reduces the virulence of Cryptococcus neoformans\/Cryptococcus gattii species complex. Microbiology (Reading). 2016;162(2):309\u201317.","journal-title":"Microbiology (Reading)"},{"issue":"7","key":"1757_CR90","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1128\/AAC.47.7.2208-2216.2003","volume":"47","author":"RC Matthews","year":"2003","unstructured":"Matthews RC, et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother. 2003;47(7):2208\u201316.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1757_CR91","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.diagmicrobio.2004.08.013","volume":"51","author":"L Nooney","year":"2005","unstructured":"Nooney L, Matthews RC, Burnie JP. Evaluation of mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis. 2005;51(1):19\u201329.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1757_CR92","unstructured":"NCT, efficacy and safety of mycograb as adjunctive therapy for cryptococcal meningitis in patients with AIDS. https:\/\/clinicaltrials.gov\/show\/NCT00324025. 2006."},{"issue":"2","key":"1757_CR93","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1021\/acs.jmedchem.0c01777","volume":"64","author":"PT Marcyk","year":"2021","unstructured":"Marcyk PT, et al. Fungal-selective resorcylate aminopyrazole Hsp90 inhibitors: optimization of whole-cell anticryptococcal activity and insights into the structural origins of cryptococcal selectivity. J Med Chem. 2021;64(2):1139\u201369.","journal-title":"J Med Chem"},{"issue":"2","key":"1757_CR94","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/jac\/dkx410","volume":"73","author":"NP Wiederhold","year":"2018","unstructured":"Wiederhold NP, et al. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus. J Antimicrob Chemother. 2018;73(2):404\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1757_CR95","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1128\/AAC.00349-16","volume":"60","author":"AGS Warrilow","year":"2016","unstructured":"Warrilow AGS, et al. The investigational drug VT-1129 is a highly potent inhibitor of Cryptococcus species CYP51 but only weakly inhibits the human enzyme. Antimicrob Agents Chemother. 2016;60(8):4530\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1757_CR96","unstructured":"https:\/\/neurapheresis.org\/. Available from: https:\/\/neurapheresis.org\/."},{"issue":"9","key":"1757_CR97","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1161\/STROKEAHA.119.025399","volume":"50","author":"SL Blackburn","year":"2019","unstructured":"Blackburn SL, et al. Prospective trial of cerebrospinal fluid filtration after aneurysmal subarachnoid hemorrhage via lumbar catheter (PILLAR). Stroke. 2019;50(9):2558\u201361.","journal-title":"Stroke"},{"issue":"7","key":"1757_CR98","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/infdis\/jiy286","volume":"218","author":"GJ Smilnak","year":"2018","unstructured":"Smilnak GJ, et al. Novel treatment of cryptococcal meningitis via neurapheresis therapy. J Infect Dis. 2018;218(7):1147\u201354.","journal-title":"J Infect Dis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01757-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01757-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01757-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T02:06:53Z","timestamp":1701050813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01757-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":98,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01757-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"24 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Drs. Day, Flower and Thuy declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data\u00a0availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the design of the review based upon a talk given by JND at the European Congress on Clinical Microbiology and Infectious Diseases in Amsterdam in 2019. NTTN and BF updated the paper, NTTN wrote the first draft; BF and JND edited the paper.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}